Aspa Therapeutics' BBP-812 Gene Therapy Program for Canavan Disease

Genevieve (Jenny) Laforet, MD, PhD Vice President, Clinical Development

02 June 2023





US-2300056 20230523

- Overview of Aspa's gene therapy program for Canavan Disease
- Overview of **CAN**inform natural history study
- Background on Aspa's investigational gene therapy, BBP-812
- CANASPIRE gene therapy clinical trial
 - -Study design, eligibility, and requirements
 - -Study sites
 - -Update on recent results
- Question and answer session







BBP-812 has not been approved by the FDA or any other regulatory authority as its efficacy and safety have not been established.





















THE LEUKODYSTROPHY CHARITY HELPING TO COPE – HELPING TO HOPE















Natural History Study

Gene Therapy Clinical Trial





CANINFORM

Canavan Disease Natural History Study







Natural History Study

RETROSPECTIVE

PROSPECTIVE

Medical Record Review

Direct Assessments of Child (optional)

- Anyone with a diagnosis of Canavan disease, living or deceased, is eligible to participate
- Study consists of medical record collection and data extraction (retrospective – all participants)
- Periodic motor, developmental and neurological assessments of enrolled patients (prospective – opt-in)
 - Most assessments done remotely via video



No cost to participate



CANINFORM Natural History Study: Worldwide Participation

55 Participants* Enrolled from 14 Countries

- Australia
- Austria
- Bulgaria
- Egypt
- Germany
- Hungary
- India
- Israel
- Panama
- Poland
- El Salvador
- Switzerland
- Syria
- Turkey
- Ukraine
- USA









CANASpire

Gene Therapy Clinical Trial

Overview






Without Canavan Disease


ASPA Enzyme Present


With Canavan Disease

ASPA Enzyme Absent



BBP-812, Aspa's Investigational Gene Therapy: Overview





- Open-label study
 - All eligible participants receive a single IV infusion of BBP-812
 - Goal is to use data from untreated patients in **CAN** inform natural history study for comparison
- Objectives
 - Learn about BBP-812 safety and tolerability: adverse events; laboratory tests; physical, neurological and eye examinations; ECGs; spinal taps
 - Is it having an impact on the disease? NAA levels, motor / developmental assessments, imaging (MRI, MRS), quality of life





CANASPIRE Eligibility and Study Requirements

- Patient Eligibility
 - Confirmed diagnosis of Canavan disease including 2 abnormal copies of the ASPA gene
 - Otherwise medically healthy with generally normal lab tests
 - Early stage of disease
 - Negative for pre-existing antibodies against AAV9
 - No active viral or bacterial infections
 - Family willing and able to participate in study visits for 5 years
- Study Requirements
 - Corticosteroids for at least 3 months before tapering
 - Imaging and spinal taps; require anesthesia & COVID-19 testing
 - Frequent blood draws





Current Study Sites

Mass. General Brigham Boston, MA, USA

Florian Eichler, MD



UCSF Benioff Children's Hospital Oakland, CA, USA

Alexander Fay, MD



Weill Cornell Medicine New York, NY, USA

Eric Mallack, MD







CANASpire

Gene Therapy Clinical Trial

Current Results





CANaspire Important Disclaimers

The following slides show early data from Aspa's investigational gene therapy BBP-812 which has not been evaluated as safe and effective by the FDA or other regulatory authorities.

These data are insufficient to determine whether reductions in NAA levels will be associated with clinical benefit to patients.

Early data from certain participants in the open-label trial are not necessarily indicative of future or final data from clinical trials.





CANaspire Current Safety Understanding

As of May 19, 2023 :


- 6 study participants have received Aspa's investigational gene therapy BBP-812
- Intravenous (IV) infusions of BBP-812 have been well-tolerated (no infusion reactions)
- All participants had at least 1 adverse event (AE); the majority were mild or moderate in severity and considered unlikely or not related to BBP-812
- 5 serious adverse events (SAEs) were reported in 3 participants; all were considered unlikely or not related to BBP-812
- To date, the safety profile of BBP-812 has been consistent with other AAV9 gene therapies given IV













~~ CAN aspire NAA Levels – Cerebrospinal Fluid (CSF) and Brain by MR Spectroscopy




Lower NAA Levels May Be Associated with Less Severe Disease







CANASPIRE Early Imaging Data - MRI






Brain MRI scans after dosing demonstrate improvements in myelin



CANASPIRE Early Clinical Data - Mobility







CANASPIRE More Understanding to Come

- Although all six participants had rapid and sustained decreases in NAA after dosing, <u>levels were still many times higher than</u> <u>normal</u>
- Despite trending evidence that lower NAA levels are related to less severe Canavan disease, <u>that does not necessarily mean that</u> <u>lowering NAA levels will make existing severe Canavan disease</u> <u>milder</u>
- <u>It is not clear whether</u> restoring ASPA activity and <u>lowering NAA</u> <u>levels will lead to clinical improvement</u> in children with Canavan



disease



Summary

- Aspa's CAN aspire gene therapy trial is currently recruiting potential participants from within and outside the US
- Preliminary results from 6 dosed participants are encouraging:
 - Generally well-tolerated to date
 - Reductions of NAA in CSF, brain tissue and urine to levels consistent with less severe Canavan disease
 - Improvement in brain myelination
 - Positive changes in head control and sitting abilities
- It is too early to determine safety, tolerability and clinical benefit, if any more data and longer follow-up are needed









Thank you!



www.treatcanavan.com

https://clinicaltrials.gov/ct2/show/NCT04126005

https://www.facebook.com/AspaTherapeutics

